When the BIOSECURE Act hit a setback and missed the chance of becoming law in 2024, the deceleration of the draft legislation ...
Our fair value estimate for WuXi is HKD 24.60 per share. WuXi has been growing at a CAGR of 53.3% for the past eight years. Although its USD 20.5 billion total backlog revenue supports our growth ...
US passed Biosecure Act which would ban federal contracts with targeted firms and their business partners. Legislation ...
In Ireland, WuXi Biologics has sold a new vaccines plant to Merck & Co. for €500 million ($521 million). The New Jersey ...
GlobalData on MSN2d
WuXi Biologics to sell Ireland-based vaccine site to MSD for $500mThe transaction is expected to close in the first half of 2025, subject to the satisfaction of customary closing conditions.
Investors also drew comfort from positive management commentary on increased client inquiries and on-site customer visits, ...
The acquisition from Wuxi Biologics, the embattled CDMO named in the BIOSECURE Act, marks another expansion of Merck’s ...
China is adapting its Life Sciences policy to bolster innovation and data transparency. Big Pharma is taking note.
JPMorgan upgraded Wuxi Biologics (WXXWY) to Overweight from Neutral with a price target of HK$20, up from HK$13, citing expected order growth ...
Chinese cybersecurity regulator details on the lenient certification method for cross-border data transfer; U.S. issues final ...
WuXi Biologics Cayman Inc. will sell a vaccine facility in Ireland to Merck & Co. for about $500 million as the Chinese ...
A summary of recent health news includes Louisiana's first bird flu death, WuXi Biologics' sale of an Irish facility to Merck ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback